According to the authors, learning more about the basic genetics of infantile hemangioma, opens new therapeutic options. Any therapy that targets vascular endothelial growth factor, that is an anti-VEGF therapy, could help infants with these tumors, especially those where clinical complications may affect their quality of life.
Although benign, ten percent of infantile hemangioma sufferers experience problems such as:
*Psychological stress because of social challenges brought on by disfigurement
*Physical complications caused by large tumors
*Obstruction of vision
*Problems with respiration
Anti-VEGF therapies, that is therapies that block the production of VEGF, have been applied successfully for other medical problems such as macular degeneration and certain types of cancer. At the present time anti-VEGF is not approved for hemangioma. But the results of this study will undoubtedly lead some to push for clinical trials to test the efficacy and safety of ant-VEGF therapies on infantile hemangioma.